Iris Dotan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6226529/publications.pdf

Version: 2024-02-01

109321 91884 5,549 124 35 69 citations h-index g-index papers 127 127 127 5896 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology, 2021, 160, 1570-1583.	1.3	1,054
2	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet, The, 2014, 384, 309-318.	13.7	421
3	Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab. Clinical Gastroenterology and Hepatology, 2015, 13, 522-530.e2.	4.4	268
4	Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 2247-2259.	1.9	232
5	Antibodies Against Laminaribioside and Chitobioside Are Novel Serologic Markers in Crohn's Disease. Gastroenterology, 2006, 131, 366-378.	1.3	219
6	Infliximab-Related Infusion Reactions: Systematic Review. Journal of Crohn's and Colitis, 2015, 9, 806-815.	1.3	178
7	Cell-centred meta-analysis reveals baseline predictors of anti-TNF \hat{l} ± non-response in biopsy and blood of patients with IBD. Gut, 2019, 68, 604-614.	12.1	153
8	Association Between Response to Etrolizumab and Expression of Integrin $\hat{1}\pm E$ and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology, 2016, 150, 477-487.e9.	1.3	133
9	Gut microbiota density influences host physiology and is shaped by host and microbial factors. ELife, 2019, 8, .	6.0	118
10	CXCL12 Is a constitutive and inflammatory chemokine in the intestinal immune system. Inflammatory Bowel Diseases, 2010, 16, 583-592.	1.9	101
11	ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation. Gut, 2015, 64, 367-372.	12.1	100
12	Probiotics in inflammatory bowel disease: possible mechanisms of action. Current Opinion in Gastroenterology, 2005, 21, 426-30.	2.3	81
13	Pouch Inflammation Is Associated With a Decrease in Specific Bacterial Taxa. Gastroenterology, 2015, 149, 718-727.	1.3	80
14	The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 49-59.	8.1	76
15	Normal Response to Vaccines in Inflammatory Bowel Disease Patients Treated with Thiopurines. Inflammatory Bowel Diseases, 2012, 18, 261-268.	1.9	73
16	Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an openâ€label, longâ€term extension study with up to 7.0Âyears of treatment. Alimentary Pharmacology and Therapeutics, 2022, 55, 464-478.	3.7	73
17	Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations: Table 1 Journal of Crohn's and Colitis, 2015, 9, 685-691.	1.3	71
18	Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-l³. American Journal of Physiology - Renal Physiology, 2007, 292, G1630-G1640.	3.4	68

#	Article	IF	CITATIONS
19	Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα. Gastroenterology, 2022, 162, 454-467.	1.3	68
20	Results of the 4th Scientific Workshop of the ECCO (Group II): Markers of intestinal fibrosis in inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, 1166-1178.	1.3	65
21	The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohnâ∈™s Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study. Journal of Crohn's and Colitis, 2016, 10, 525-531.	1.3	64
22	Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 519-528.	8.1	63
23	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. Digestive Diseases, 2019, 37, 266-283.	1.9	63
24	Enterococcus faecalis Gelatinase Mediates Intestinal Permeability via Protease-Activated Receptor 2. Infection and Immunity, 2015, 83, 2762-2770.	2,2	62
25	Sequential capsule endoscopy of the small bowel for follow-up of patients with known Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 1616-1623.	1.3	61
26	Comparing diagnostic yield of a novel pan-enteric video capsule endoscope with ileocolonoscopy in patients with active Crohn's disease: a feasibility study. Gastrointestinal Endoscopy, 2017, 85, 196-205.e1.	1.0	61
27	The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational antiâ€integrin therapies. Medicinal Research Reviews, 2020, 40, 245-262.	10.5	60
28	Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice. Nature Genetics, 2021, 53, 500-510.	21.4	56
29	Predominantly Antibiotic-resistant Intestinal Microbiome Persists in Patients With Pouchitis Who Respond to Antibiotic Therapy. Gastroenterology, 2020, 158, 610-624.e13.	1.3	53
30	COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation. Clinical Gastroenterology and Hepatology, 2022, 20, e1263-e1282.	4.4	53
31	New Serologic Markers for Inflammatory Bowel Disease Diagnosis. Digestive Diseases, 2010, 28, 418-423.	1.9	52
32	Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Digestive Diseases and Sciences, 2001, 46, 2239-2244.	2.3	50
33	A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut, 2010, 59, 760-766.	12.1	49
34	Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study. Clinical Epidemiology, 2018, Volume 10, 671-681.	3.0	48
35	Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. The Lancet Gastroenterology and Hepatology, 2022, 7, 17-27.	8.1	44
36	Magnetic resonance enterography <i>versus</i> capsule endoscopy activity indices for quantification of small bowel inflammation in Crohn's disease. Therapeutic Advances in Gastroenterology, 2016, 9, 655-663.	3.2	41

#	Article	IF	CITATIONS
37	Helicobacter pylori infection is positively associated with an increased BMI, irrespective of socioeconomic status and other confounders: a cohort study. European Journal of Gastroenterology and Hepatology, 2018, 30, 143-148.	1.6	36
38	Clock Gene Disruption Is an Initial Manifestation of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 115-122.e1.	4.4	36
39	Carriage of Colibactin-producing Bacteria and Colorectal Cancer Risk. Trends in Microbiology, 2020, 28, 874-876.	7.7	36
40	Maternal inflammatory bowel disease has short and long-term effects on the health of their offspring: A multicenter study in Israel. Journal of Crohn's and Colitis, 2013, 7, 542-550.	1.3	35
41	Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. United European Gastroenterology Journal, 2020, 8, 1076-1085.	3.8	35
42	Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review. Expert Review of Gastroenterology and Hepatology, 2021, 15, 985-997.	3.0	35
43	The Association of Inflammatory Bowel Diseases with Autoimmune Disorders: A Report from the epi-IIRN. Journal of Crohn's and Colitis, 2019, 13, 324-329.	1.3	32
44	Alterations of Enteric Microbiota in Patients with a Normal Ileal Pouch Are Predictive of Pouchitis. Journal of Crohn's and Colitis, 2017, 11, 314-320.	1.3	28
45	Epidemiology of Inflammatory Bowel Diseases in Israel: A Nationwide Epi-Israeli IBD Research Nucleus Study. Inflammatory Bowel Diseases, 2021, 27, 1784-1794.	1.9	26
46	Association between time to colonoscopy after a positive guaiac fecal test result and risk of colorectal cancer and advanced stage disease at diagnosis. International Journal of Cancer, 2020, 146, 1532-1540.	5.1	25
47	Magnetic resonance enterography or video capsule endoscopy & amp; ndash; what do Crohn& amp; rsquo; s disease patients prefer?. Patient Preference and Adherence, 2016, 10, 1043.	1.8	24
48	Prevention of Antidrug Antibody Formation to Infliximab inÂCrohn's Patients With Prior Failure of Thiopurines. Clinical Gastroenterology and Hepatology, 2017, 15, 69-75.	4.4	24
49	Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes. American Journal of Gastroenterology, 2019, 114, 900-906.	0.4	24
50	Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel diseaseâ€"The Israeli real world experience. Digestive and Liver Disease, 2019, 51, 68-74.	0.9	24
51	Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study. United European Gastroenterology Journal, 2020, 8, 418-424.	3.8	24
52	Gene expression alterations in ulcerative colitis patients after restorative proctocolectomy extend to the small bowel proximal to the pouch. Gut, 2015, 64, 756-764.	12.1	22
53	Randomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease. Inflammatory Bowel Diseases, 2022, 28, 393-408.	1.9	21
54	Colectomy Rates did not Decrease in Paediatric- and Adult-Onset Ulcerative Colitis During the Biologics Era: A Nationwide Study From the epi-IIRN. Journal of Crohn's and Colitis, 2022, 16, 796-803.	1.3	21

#	Article	IF	CITATIONS
55	Disease Behavior in Adult Patients: Are There Predictors for Stricture or Fistula Formation?. Digestive Diseases, 2009, 27, 206-211.	1.9	20
56	Restorative Proctocolectomy in Elderly IBD Patients: A Multicentre Comparative Study on Safety and Efficacy. Journal of Crohn's and Colitis, 2017, 11, jjw209.	1.3	20
57	Significance of low level infliximab in the absence of anti-infliximab antibodies. World Journal of Gastroenterology, 2015, 21, 1907.	3.3	19
58	MicroRNAs Expression in the Ileal Pouch of Patients with Ulcerative Colitis Is Robustly Up-Regulated and Correlates with Disease Phenotypes. PLoS ONE, 2016, 11, e0159956.	2.5	19
59	Dysbiosis in Metabolic Genes of the Gut Microbiomes of Patients with an Ileo-anal Pouch Resembles That Observed in Crohn's Disease. MSystems, 2021, 6, .	3.8	19
60	Clinical outcomes of endoscopic balloon dilatation of intestinal strictures in patients with Crohn's disease. Medicine (United States), 2019, 98, e16864.	1.0	17
61	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach. Intestinal Research, 2018, 16, 522-528.	2.6	17
62	Of mice and men: a novel dietary supplement for the treatment of ulcerative colitis. Therapeutic Advances in Gastroenterology, 2018, 11, 1756283X1774186.	3.2	16
63	Improved Outcomes of Paediatric and Adult Crohn's Disease and Association With Emerging Use of Biologics–A Nationwide Study From the Epi-IIRN. Journal of Crohn's and Colitis, 2022, 16, 778-785.	1.3	16
64	Perianal Crohn's Disease Is Associated With Poor Disease Outcome: A Nationwide Study From the epillRN Cohort. Clinical Gastroenterology and Hepatology, 2022, 20, e484-e495.	4.4	15
65	Optimization of ¹³ Câ€urea breath test threshold levels for the detection of <i>Helicobacter pylori</i> infection in a national referral laboratory. Journal of Clinical Laboratory Analysis, 2019, 33, e22674.	2.1	14
66	Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial. Digestive Diseases and Sciences, 2016, 61, 3246-3254.	2.3	13
67	Improvement in the implementation of Helicobacter pylori management guidelines among primary care physicians following a targeted educational intervention. Annals of Gastroenterology, 2018, 32, 52-59.	0.6	13
68	Risk of Cancer in Paediatric onset Inflammatory Bowel Diseases: A Nation-wide Study From the epi-IIRN. Journal of Crohn's and Colitis, 2022, 16, 786-795.	1.3	13
69	Risk of Neoplastic Progression Among Patients with an Irregular Z Line on Long-Term Follow-Up. Digestive Diseases and Sciences, 2018, 63, 1513-1517.	2.3	12
70	Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force. Journal of Crohn's and Colitis, 2020, 14, S785-S790.	1.3	12
71	Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNF \hat{l} ± therapy in inflammatory bowel disease patients: a report from the epi-llRN. Gut, 2022, 71, 287-295.	12.1	12
72	Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel. Digestive and Liver Disease, 2022, 54, 192-197.	0.9	12

#	Article	IF	CITATIONS
73	Realâ€world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease: <scp>ERELATE</scp> Study. Alimentary Pharmacology and Therapeutics, 2022, 56, 463-476.	3.7	12
74	Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable. Clinical Gastroenterology and Hepatology, 2021, 19, 1564-1572.e5.	4.4	11
75	Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification. Expert Review of Gastroenterology and Hepatology, 2007, 1, 265-274.	3.0	10
76	Endoscopic findings and esophageal cancer incidence among Fanconi Anemia patients participating in an endoscopic surveillance program. Digestive and Liver Disease, 2019, 51, 242-246.	0.9	10
77	Association Between Polyp Detection Rate and Post-Colonoscopy Cancer Among Patients Undergoing Diagnostic Colonoscopy. Clinical Gastroenterology and Hepatology, 2021, 19, 202-204.	4.4	10
78	Alteration in Urease-producing Bacteria in the Gut Microbiomes of Patients with Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2021, 15, 2066-2077.	1.3	10
79	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment® ^{MMX®}) for active, mildâ€ŧoâ€moderate ulcerative colitis. United European Gastroenterology Journal, 2019, 7, 1171-1182.	3.8	9
80	Starch Consumption May Modify Antiglycan Antibodies and Fecal Fungal Composition in Patients With Ileo-Anal Pouch. Inflammatory Bowel Diseases, 2019, 25, 742-749.	1.9	9
81	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clinical Gastroenterology and Hepatology, 2022, 20, 2619-2627.e1.	4.4	9
82	Correlation between Quantitative ¹³ C-Urea Breath Test and <i>Helicobacter pylori</i> Treatment Success in a Population-Based Cohort. Gastroenterology Research and Practice, 2018, 2018, 1-6.	1.5	8
83	Faecal Proteases from Pouchitis Patients Activate Protease Activating Receptor-2 to Disrupt the Epithelial Barrier. Journal of Crohn's and Colitis, 2019, 13, 1558-1568.	1.3	8
84	Neutrophil to lymphocyte ratio and risk of neoplastic progression in patients with Barrett's esophagus. Endoscopy, 2020, 53, 774-781.	1.8	8
85	Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clinical Gastroenterology and Hepatology, 2021, 19, 2444-2446.e2.	4.4	8
86	Commensal fungi and their cellâ€wall βâ€glucans direct differential responses in human intestinal epithelial cells. European Journal of Immunology, 2021, 51, 864-878.	2.9	8
87	Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents. Journal of Crohn's and Colitis, 2015, 9, 382-389.	1.3	7
88	Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. BMJ Open Gastroenterology, 2016, 3, e000092.	2.7	7
89	Increase in Processing Factors Is Involved in Skewed MicroRNA Expression in Patients with Ulcerative Colitis Who Develop Small Intestine Inflammation after Pouch Surgery. Inflammatory Bowel Diseases, 2018, 24, 1045-1054.	1.9	7
90	Exploring Popular Social Media Networks for Patients With Inflammatory Bowel Diseases. Journal of Clinical Gastroenterology, 2022, 56, e203-e208.	2.2	7

#	Article	IF	CITATIONS
91	Fecal Calprotectin Is Increased in Pouchitis and Progressively Increases With More Severe Endoscopic andÂHistologic Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 1839-1846.e2.	4.4	7
92	Crohn's Disease Behavior and Location is Altered when Associated with Primary Sclerosing Cholangitis. Israel Medical Association Journal, 2018, 20, 25-29.	0.1	7
93	Long-term Antibiotic Treatment in Pouchitis—Patterns of Use and Safety. Inflammatory Bowel Diseases, 2022, 28, 1027-1033.	1.9	6
94	Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. The Lancet Gastroenterology and Hepatology, 2022, 7, 390-391.	8.1	6
95	Advanced technology for assessment of endoscopic and histological activity in ulcerative colitis: a systematic review and meta-analysis. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210925.	3.2	6
96	Prediction of renal impairment in elderly patients with congestive heart failure treated with captopril. Cardiovascular Drugs and Therapy, 1996, 10, 75-79.	2.6	5
97	Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482110686.	3.2	5
98	<i>Escherichia coli</i> Strains from Patients with Inflammatory Bowel Diseases have Disease-specific Genomic Adaptations. Journal of Crohn's and Colitis, 2022, 16, 1584-1597.	1.3	5
99	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. Journal of Crohn's and Colitis, 2019, 13, 539-540.	1.3	4
100	<p>Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1</p> . Clinical and Experimental Gastroenterology, 2020, Volume 13, 211-220.	2.3	4
101	Machine learning for selecting patients with Crohn's disease for abdominopelvic computed tomography in the emergency department. Digestive and Liver Disease, 2021, 53, 1559-1564.	0.9	4
102	Incidence of Colorectal Adenomas After Bariatric Surgery: Pre-operative Super Morbid Obesity Is Independently Associated with Increased Risk. Obesity Surgery, 2021, 31, 4220-4226.	2.1	4
103	Meta-Analysis of IBD Gut Samples Gene Expression Identifies Specific Markers of Ileal and Colonic Diseases. Inflammatory Bowel Diseases, 2022, 28, 775-782.	1.9	4
104	Predictors for poor outcome of hospitalized children with inflammatory bowel disease. European Journal of Pediatrics, 2020, 179, 157-164.	2.7	3
105	Comparative Effect of Proton-Pump Inhibitors on the Success of Triple and Quadruple Therapy for <i>Helicobacter pylori</i> Infection. Digestive Diseases, 2020, 38, 408-414.	1.9	3
106	Doseâ€dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pyloriâ€positive patients. United European Gastroenterology Journal, 2021, 9, 343-353.	3.8	3
107	Altered thyroid status modulates portal pressure in normal rats. Liver International, 1999, 19, 423-426.	3.9	2
108	Video capsule endoscopy is safe and effective in suspected small bowel bleeding among left ventricular assist device recipients. International Journal of Artificial Organs, 2018, 41, 833-837.	1.4	2

#	Article	IF	CITATIONS
109	Pediatricâ€onset Inflammatory Bowel Disease Has Only a Modest Effect on Final Growth. Journal of Pediatric Gastroenterology and Nutrition, 2021, 73, 223-230.	1.8	2
110	Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinic. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110531.	3.2	2
111	Evaluating IBD-specific antiglycan antibodies in serum of patients with spondyloarthritis and rheumatoid arthritis: are they really specific?. Clinical and Experimental Rheumatology, 2019, 37, 32-36.	0.8	2
112	NOD2 and pouch complications in UC patients: old-world clinical dogmas give way to biological definitions. Gut, 2013, 62, 1390-1391.	12.1	1
113	Young GI Angle: What makes for a good mentor?. United European Gastroenterology Journal, 2016, 4, 320-320.	3.8	1
114	Venous Thromboembolism Among Patients With Inflammatory Bowel Diseases is Not Related to Increased Thrombophilia. Journal of Clinical Gastroenterology, 2021, Publish Ahead of Print, .	2.2	1
115	Reply to Antibiotic Use Patterns in the Management of Chronic Pouchitis. Inflammatory Bowel Diseases, 2022, , .	1.9	1
116	COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience. Vaccines, 2022, 10, 376.	4.4	1
117	Inflammatory bowel disease and colorectal cancer: What is new?. Current Colorectal Cancer Reports, 2009, 5, 35-39.	0.5	0
118	MicroRNA-132 Modulates Cholinergic Signaling and Inflammation in Human Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2012, 18, S105-S106.	1.9	0
119	Reply. Gastroenterology, 2020, 159, 401-402.	1.3	0
120	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 1504-1505.	4.4	0
121	Endoscopic Assessment of the Pouch: An Essential Step Forward. Journal of Crohn's and Colitis, 2022, 16, 1-1.	1.3	0
122	OMO-2â€Filgotinib efficacy in patients with ulcerative colitis by line of therapy: Phase 2b/3 selection results., 2021,,.		0
123	The risk of advanced neoplasia after polypectomy of one to two non-advanced adenomas less than 5Âmm in size vs. normal colonoscopy. Digestive and Liver Disease, 2022, , .	0.9	0
124	A novel endoscopic technique for closure of two gastro-gastric fistulas in a single session using an endoscopic helix tacking device. Endoscopy, 0, , .	1.8	0